EYEPOINT PHARMACEUTICALS INC (EYPT)
US30233G2093 - Common Stock
We assign a fundamental rating of 4 out of 10 to EYPT. EYPT was compared to 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for EYPT as it has an excellent financial health rating, but there are worries on the profitability. EYPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EYPT had negative earnings in the past year.
EYPT had a negative operating cash flow in the past year.
EYPT had negative earnings in each of the past 5 years.
EYPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
EYPT has a Return On Assets of -26.78%. This is comparable to the rest of the industry: EYPT outperforms 58.33% of its industry peers.
Looking at the Return On Equity, with a value of -38.03%, EYPT is in the better half of the industry, outperforming 63.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.78% | ||
| ROE | -38.03% | ||
| ROIC | N/A |
ROA(3y)-32.93%
ROA(5y)-45.22%
ROE(3y)-54.78%
ROE(5y)-218.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EYPT has a Gross Margin of 91.35%. This is amongst the best in the industry. EYPT outperforms 95.83% of its industry peers.
EYPT's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for EYPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.68%
GM growth 5YN/A
2. Health
2.1 Basic Checks
EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
EYPT has more shares outstanding than it did 1 year ago.
EYPT has more shares outstanding than it did 5 years ago.
EYPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of 0.11, we must say that EYPT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.11, EYPT is in line with its industry, outperforming 48.96% of the companies in the same industry.
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.11 |
ROIC/WACCN/A
WACC8.96%
2.3 Liquidity
EYPT has a Current Ratio of 4.75. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.75, EYPT is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
EYPT has a Quick Ratio of 4.69. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
EYPT's Quick ratio of 4.69 is fine compared to the rest of the industry. EYPT outperforms 66.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.75 | ||
| Quick Ratio | 4.69 |
3. Growth
3.1 Past
EYPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.81%, which is quite impressive.
Looking at the last year, EYPT shows a quite strong growth in Revenue. The Revenue has grown by 11.15% in the last year.
The Revenue has been growing by 73.11% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)24.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.64%
Revenue 1Y (TTM)11.15%
Revenue growth 3Y10.14%
Revenue growth 5Y73.11%
Sales Q2Q%-30.77%
3.2 Future
EYPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.39% yearly.
Based on estimates for the next years, EYPT will show a very strong growth in Revenue. The Revenue will grow by 50.39% on average per year.
EPS Next Y-28.99%
EPS Next 2Y-31.8%
EPS Next 3Y-23.64%
EPS Next 5Y18.39%
Revenue Next Year7.59%
Revenue Next 2Y-40.24%
Revenue Next 3Y-40.17%
Revenue Next 5Y50.39%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EYPT. In the last year negative earnings were reported.
Also next year EYPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as EYPT's earnings are expected to decrease with -23.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.8%
EPS Next 3Y-23.64%
5. Dividend
5.1 Amount
No dividends for EYPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EYEPOINT PHARMACEUTICALS INC
NASDAQ:EYPT (11/22/2024, 6:27:08 PM)
After market: 9.08 +0.13 (+1.45%)8.95
+0.6 (+7.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap609.50M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.78% | ||
| ROE | -38.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.35% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.75 | ||
| Quick Ratio | 4.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)24.81%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-28.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.15%
Revenue growth 3Y10.14%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y